Evidence map›Paper›PMID 31390330›Full record

ArticleTurkish thoracic journal2019

Airway Clearance with Expiratory Flow Accelerator Technology: Effectiveness of the "Free Aspire" Device in Patients with Severe COPD.

Giorgia Patrizio, Michele D'Andria, Francesco D'Abrosca, Antonella Cabiaglia, Fabio Tanzi, Giancarlo Garuti, Antonello Nicolini

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish thoracic journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05993364 (Role of Expiratory Flow Acceleration in the Management of Bronchial Secrections in Severe Acquired Brain Injury), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05993364 narecruitingnot on this mapstarted 2024, after this paper: background citation

Role of Expiratory Flow Acceleration in the Management of Bronchial Secrections in Severe Acquired Brain Injury: a Pilot Randomized Controlled Study

TypeinterventionalSponsorFondazione Don Carlo Gnocchi ETSRan2024 to 2025Enrolled20ConditionsAcquired Brain Injury, Comparative Effectiveness Research, Lung Diseases, ObstructiveArmsFree Aspire with Expiratory Flow Accelerator (EFA) technology, In-Exufflator Machine, Traditional respiratory treatment, Traditional swallowing treatment
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Giorgia PatrizioPulmonology and Rehabilitation Unit, Cuasso al Monte Hospital, Varese, Italy.ORCID http://orcid.org/0000-0003-1508-641X
Michele D'AndriaPhysiotherapy Degree Course, Insubria University, Varese, Italy.ORCID http://orcid.org/0000-0001-5792-8270
Francesco D'AbroscaSITRA, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID http://orcid.org/0000-0003-0505-2371
Antonella CabiagliaPulmonology and Rehabilitation Unit, Cuasso al Monte Hospital, Varese, Italy.ORCID http://orcid.org/0000-0001-8834-7145
Fabio TanziPhysical Medicine and Rehabilitation, General Hospital, Varese, Italy.ORCID http://orcid.org/0000-0003-3317-0252
Giancarlo GarutiPulmonology Unit, Santa Maria Bianca Hospital, Mirandola, Italy.ORCID http://orcid.org/0000-0002-3904-820X
Antonello NicoliniRespiratory Diseases Unit, General Hospital Sestri Levante, Sestri Levante, Italy.ORCID http://orcid.org/0000-0001-8286-7406

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesChronic obstructive pulmonary disease (COPD) is associated with a higher risk of pulmonary infections. This risk not only negatively affects patients' quality of life but also increases social and health costs. Hence, there is a need for an effective rehabilitative treatment including airway clearance. The aim of this pilot study was to evaluate the efficacy of a new tool for bronchial clearance based on expiratory flow accelerator (EFA) technology compared with positive expiratory pressure (PEP) treatment. MATERIALS AND

methodsTwenty stable patients with COPD, Global Initiative for Chronic Obstructive Lung Disease 3-4 stage, were enrolled and allocated to treatment with EFA or Bubble-PEP (BP) for 20 days during a pulmonary rehabilitation program. At baseline and the end of treatment, the following parameters were measured: arterial blood gases (ABG); respiratory function, including peak cough expiratory flow (PCEF), maximal inspiratory pressure (MIP), and maximal expiratory pressure exercise capacity using the 6-minute walk test (6MWT), dyspnea using the Medical Research Council scale, and quality of life using the St. George's Respiratory Questionnaire.

resultsExpiratory flow accelerator showed a significant pre- and post-improvement in ABG and a significantly greater improvement than BP in PCEF, MIP, and 6MWT post-treatment.

conclusionExpiratory flow accelerator is a valid device compared with BP as an adjunctive therapy for the treatment of patients with severe COPD.

Identifiers

PMID31390330
PMCPMC6777661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.